Stock A352770 CLINOMICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Clinomics Inc.

Equities

A352770

KR7352770002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 13/05/2024 BST 		5-day change 1st Jan Change
1,436 KRW +5.51% Intraday chart for Clinomics Inc. -14.06% -44.02%
05-03 Clinomics Inc. agreed to acquire New Oriental Hotel Co., Ltd from Daon Engineering Co., Ltd and Gi-dong Song for KRW 18.5 billion. CI
2023 Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd. CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 225,541 170,350 88,076 82,006
Enterprise Value (EV) 1 196,425 143,213 90,618 88,941
P/E ratio -13.3 x 13 x -8.62 x -1.63 x
Yield - - - -
Capitalization / Revenue 23 x 3.07 x 3.82 x 7.19 x
EV / Revenue 20 x 2.58 x 3.93 x 7.8 x
EV / EBITDA -18.9 x 5.6 x -13.3 x -2.93 x
EV / FCF -20.7 x 19.8 x -4.11 x -43.5 x
FCF Yield -4.83% 5.06% -24.3% -2.3%
Price to Book 5.65 x 2.91 x 1.66 x 2.12 x
Nbr of stocks (in thousands) 19,499 19,732 19,957 31,971
Reference price 2 11,567 8,633 4,413 2,565
Announcement Date 16/03/21 18/03/22 20/03/23 21/03/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 9,820 55,426 23,083 11,408
EBITDA 1 -10,399 25,567 -6,815 -30,337
EBIT 1 -12,259 22,924 -10,833 -34,588
Operating Margin -124.84% 41.36% -46.93% -303.2%
Earnings before Tax (EBT) 1 -13,146 24,819 -10,122 -42,431
Net income 1 -13,147 15,853 -10,177 -42,257
Net margin -133.88% 28.6% -44.09% -370.43%
EPS 2 -871.3 662.1 -512.1 -1,571
Free Cash Flow 1 -9,483 7,246 -22,065 -2,047
FCF margin -96.57% 13.07% -95.59% -17.94%
FCF Conversion (EBITDA) - 28.34% - -
FCF Conversion (Net income) - 45.71% - -
Dividend per Share - - - -
Announcement Date 16/03/21 18/03/22 20/03/23 21/03/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - 2,543 6,935
Net Cash position 1 29,115 27,138 - -
Leverage (Debt/EBITDA) - - -0.3731 x -0.2286 x
Free Cash Flow 1 -9,483 7,246 -22,065 -2,047
ROE (net income / shareholders' equity) -58.5% 32.2% -17.8% -85.4%
ROA (Net income/ Total Assets) -21.7% 19.6% -6.78% -25.2%
Assets 1 60,652 80,964 150,083 167,709
Book Value Per Share 2 2,047 2,971 2,653 1,208
Cash Flow per Share 2 658.0 853.0 431.0 346.0
Capex 1 4,333 5,492 7,727 1,559
Capex / Sales 44.13% 9.91% 33.48% 13.67%
Announcement Date 16/03/21 18/03/22 20/03/23 21/03/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CLINOMICS INC. Stock Clinomics Inc.
-44.02% 34.53M
MODERNA, INC. Stock Moderna, Inc.
+29.03% 49.18B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+43.45% 40.37B
CELLTRION, INC. Stock Celltrion, Inc.
-5.26% 28.85B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.48% 26.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.74% 18.71B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+9.06% 13.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.01% 12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.51% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A352770 Stock
  4. Financials Clinomics Inc.